Post by JHam on Jul 28, 2014 18:20:53 GMT
www.4-traders.com/BRAINSTORM-CELL-THERAPEUT-146414/news/Brainstorm-Cell-Therapeutics-Inc--BrainStorm-Receives-Notice-of-Allowance-on-US-Patent-18806167/
Brainstorm Cell Therapeutics Inc : BrainStorm Receives Notice of Allowance on US Patent
07/28/2014 | 09:50am US/EasternRecommend:
0
NEW YORK, NY and PETACH TIKVAH, Israel / ACCESSWIRE / July 28, 2014 / BrainStorm Cell Therapeutics Inc. (OTCQB: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, received Notice of Allowance from the United States Patent Office for Patent Application 12/994,761, titled "Mesenchymal Stem Cells for the Treatment of CNS Diseases."
This patent covers the use of mesenchymal stem cells that secrete elevated levels of brain-derived neurotrophic factor (BDNF) to treat diseases of the central nervous system, including but not limited to Amyotrophic Lateral Sclerosis (ALS), Parkinson?s disease, Alzheimer?s disease, Huntington?s disease, multiple sclerosis, among others. The Patent Office recognized a priority date for this patent of May 28, 2008.
"We are gratified that the US Patent Office has recognized the innovative nature of NurOwn, our proprietary, differentiated mesenchymal stem cells, for use in treating a variety of neurologic diseases," commented BrainStorm?s CEO Tony Fiorino, MD, PhD., "This important patent represents yet another step forward in our intellectual property strategy, and we continue to aggressively pursue patents on all of our commercially important discoveries."
This patent falls under the company?s licensing agreement with Ramot, the technology transfer organization of Tel Aviv University, and reflects the continued collaboration between the company and the laboratory of Prof. Dani Offen, the company's chief scientist.
Brainstorm Cell Therapeutics Inc : BrainStorm Receives Notice of Allowance on US Patent
07/28/2014 | 09:50am US/EasternRecommend:
0
NEW YORK, NY and PETACH TIKVAH, Israel / ACCESSWIRE / July 28, 2014 / BrainStorm Cell Therapeutics Inc. (OTCQB: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, received Notice of Allowance from the United States Patent Office for Patent Application 12/994,761, titled "Mesenchymal Stem Cells for the Treatment of CNS Diseases."
This patent covers the use of mesenchymal stem cells that secrete elevated levels of brain-derived neurotrophic factor (BDNF) to treat diseases of the central nervous system, including but not limited to Amyotrophic Lateral Sclerosis (ALS), Parkinson?s disease, Alzheimer?s disease, Huntington?s disease, multiple sclerosis, among others. The Patent Office recognized a priority date for this patent of May 28, 2008.
"We are gratified that the US Patent Office has recognized the innovative nature of NurOwn, our proprietary, differentiated mesenchymal stem cells, for use in treating a variety of neurologic diseases," commented BrainStorm?s CEO Tony Fiorino, MD, PhD., "This important patent represents yet another step forward in our intellectual property strategy, and we continue to aggressively pursue patents on all of our commercially important discoveries."
This patent falls under the company?s licensing agreement with Ramot, the technology transfer organization of Tel Aviv University, and reflects the continued collaboration between the company and the laboratory of Prof. Dani Offen, the company's chief scientist.